Surface Oncology (SURF – Research Report) received a Hold rating and price target from JonesTrading analyst Soumit Roy today. The company’s shares closed today at $0.84.
According to TipRanks, Roy is an analyst with an average return of -3.1% and a 28.54% success rate. Roy covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Anavex Life Sciences, and Monopar Therapeutics Inc.
Surface Oncology has an analyst consensus of Hold, with a price target consensus of $2.38, implying a 183.33% upside from current levels. In a report released today, Robert W. Baird also downgraded the stock to a Hold with a $1.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Surface Oncology’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $19.74 million. In comparison, last year the company earned a revenue of $30 million and had a net profit of $6.2 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Surface Oncology, Inc. is a clinical-stage immuno-oncology company, which focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.
Read More on SURF:
